Modality | Pheochromocytoma (n = 65) | Not pheochromocytoma* (n = 27) | All patients† (n = 96) |
---|---|---|---|
18F-F-DA+ | 7/48 (14.6%) | 4/15 (26.6%) | 12/67 (17.9%) |
18F-F-DA− | 41/48 (85.4%) | 11/15 (73.4%) | 55/67 (82.1%) |
18F-FDG+ | 13/59 (22%) | 2/21 (9.5%) | 16/83 (19.3%) |
18F-FDG− | 46/59 (78%) | 19/21 (90.5%) | 67/83 (80.7%) |
123I-MIBG+ | 7/45 (15.5%) | 3/16 (18.8%) | 11/62 (17.7%) |
123I-MIBG− | 38/45 (84.5%) | 13/16 (81.2%) | 51/62 (82.3%) |